Loading…
← CockpitCompetitor Analysis › BHC.TO Bausch Health Companies Inc.Open in the cockpit ↗

Bausch Health Companies Inc.BHC.TOCompetitor analysis, valuation and peers

Canada · CAD·Health Care›Pharmaceuticals: Other

Specialty pharmaceutical company selling gastrointestinal, dermatology, neurology and international generics products.

Momentum leader 99
Mkt cap
$3.27B
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$6.48M
20-day average traded
Fwd P/E
2.0×
forward earnings
ROIC−WACC
+6.5 pp
WACC 5.0%
Hurdle
-21 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · CADC$12.52
1D+3.5%
1W+5.1%
1M+39.0%
3M+32.1%
6M+65.6%
YTD+31.4%
1Y+45.2%
ATR %3.9%
52w lowhigh1.1% off high

What Bausch Health Companies does

Specialty pharmaceutical company selling gastrointestinal, dermatology, neurology and international generics products.

Revenue comes mainly from branded prescription drugs and medical devices, where patents and regulatory exclusivity allow firm pricing, plus the eye-care business Bausch + Lomb, which it listed in 2022 while keeping control. Heavy debt left from the Valeant-era acquisition spree means a large share of cash flow goes to servicing and refinancing it.

Products and services

  • Salix gastroenterology (e.g., Xifaxan)
  • Solta Medical aesthetics devices
  • International Rx & generics

Customers

  • Physicians/GI specialists
  • Dermatologists/aesthetic clinics
  • Pharmacies/distributors

Where it sits in the supply chain

  • Pharmaceuticals
  • Specialty/branded generics
  • Multi-therapeutic portfolio (GI, derm…

What could go right

  • Deconsolidation/monetization of Bausch + Lomb stake
  • Debt reduction improving equity value

What could go wrong

  • Very high legacy debt load
  • Xifaxan patent cliff/generic competition risk

Moat: narrow (IP / patents, distribution). Xifaxan and other branded drugs have patent/exclusivity protection and established prescriber relationships.

Headquarters: Laval, Canada · Employees: 20,300

Named competitors

Bausch Health Companies at a glance

Size Bausch Health Companies (BHC.TO) is a Canada Health Care company (Pharmaceuticals: Other) with a market value of $3.27B, the 147th largest of 405 Canada companies the cockpit tracks. Shares closed at C$12.52 on 18 Nov 2026.

Performance Over six months the shares gained 65.6%, against -1.6% for the median peer and +1.1% for the Canada market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 10.1% over the last twelve months (peer median +8.1%); the operating margin is 27.2% (peer median 14.3%).

Valuation It trades at 2.0× forward earnings against a peer median of 17.8× (cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -21 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.5 points above its cost of capital (5.0% WACC).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026BHC.TO 166Peer median 99
Six months, rebased to 100: Bausch Health Companies against the median of its 20 peers (local-currency closes).

Bausch Health Companies financials

Reported figures in CAD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueC$15.4BC$14.3BC$13.2BC$11.8BC$10.6B
Revenue growth—+9%+12%+12%—
Gross profitC$9.91BC$8.74BC$7.90BC$6.91BC$5.92B
EBITDAC$5.79BC$4.74BC$4.28BC$3.87BC$3.63B
Net income-C$1.14BC$219M-C$63.0M-C$799M-C$293M
Free cash flowC$2.58BC$1.34BC$1.72BC$1.05B-C$1.32B
Capital expenditureC$530MC$569MC$466MC$367MC$349M
Total debtC$29.4BC$28.9BC$31.4BC$29.8BC$28.5B

Quarterly statements and history in the cockpit →

Bausch Health Companies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%0023170006230026033001466000626007501112000423600056300363600216SUDEEPPHRMABVXJWEL6472PHMCRONBHC.TO6-month return →1-month return →
Up and to the right = strong over both horizons. Bausch Health Companies is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×50×0023170026033001466000626007501112000423GRANULES600216SUDEEPPHRMJWEL6472BIOG-BPHMCRONBHC.TORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bausch Health Companies is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%002317000623002603600062600750000423GRANULES300363600216JWEL6472PHMCRONBHC.TOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bausch Health Companies is the large dot.

Bausch Health Companies competitors and peer comparison

Head to head with its named competitors (BHC.TO vs BLCO.TO vs OGN vs VTRS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bausch Health Companies BHC.TO$3.27B+66%+10%27%2.0×-14.8%
Bausch + Lomb BLCO.TO$7.41B+35%+11%9%18.3×12.0%
Organon & OGN$3.66B+3%-3%20%4.0×-4.1%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%
Galderma GALD.SW$51.9B+18%+16%19%45.7×18.0%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%

How Bausch Health Companies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bausch Health Companies against its 20 peers (data as of 18 Nov 2026)
MeasureBHC.TOPeer medianRank in peer set
1-month return+39.0%-1.3%highest of 21
6-month return+65.6%-1.6%3rd highest of 21
Distance from 52-week high-1.1%-23.4%2nd highest of 21
Revenue growth (TTM)+10.1%+8.1%10th highest of 20
Operating margin27.2%14.3%5th highest of 20
Forward P/E2.0×17.8×cheapest of 16
Growth the price implies (Req g, 7 yrs)-14.8%1.8%least demanding of 19
Growth delivered (Del g)+5.9%+8.1%9th lowest of 19
Hurdle (Req g minus delivered)-20.7 pp-7.0 pp2nd least demanding of 19
ROIC minus cost of capital+6.5 pp+2.6 pp8th highest of 20
EV / EBITDA5.5×18.1×cheapest of 9
Net debt / EBITDA4.5×0.0×2nd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
By-health 300146.SZChina$2.56B-1%+10%11%24.7×4.8%+0.6%
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%9.3×-9.1%+5.3%
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%16.5×-1.9%+11.6%
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%13.2×-1.7%+4.4%
Dong-E-E-Jiao 000423.SZChina$4.99B+1%+8%29%17.8×-3.7%+14.5%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Abivax ABVX.PAFrance$7.36B-30%n/an/an/an/an/a
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%

Questions

Who are Bausch Health Companies's main competitors?
Named competitors: Bausch + Lomb (BLCO.TO), Endo International (private or unlisted), Organon (OGN), Viatris (VTRS), Galderma (GALD.SW), Takeda Pharmaceutical (4502.T). The cockpit's measured peer set (industry) also includes Guangdong Zhongsheng Pharmaceutical (002317.SZ), Jilin Aodong Pharmaceutical (000623.SZ), Shijiazhuang Yiling Pharmaceutical (002603.SZ), By-health (300146.SZ), China Resources Double-Crane Pharmaceutical (600062.SS), China Resources Jiangzhong Pharmaceutical (600750.SS).
Is Bausch Health Companies expensive compared with its peers?
On forward p/e it trades at 2.0× against a peer median of 17.8×, cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -21 pp: the price already allows for a slowdown.
How has Bausch Health Companies stock performed?
Over six months to 18 Nov 2026 the shares returned +65.6% against -1.6% for the median peer; over one year +45.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.